Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Short Interest Update

Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) was the recipient of a large growth in short interest in January. As of January 30th, there was short interest totaling 12,685,342 shares, a growth of 87.3% from the January 15th total of 6,772,644 shares. Approximately 4.9% of the shares of the stock are sold short. Based on an average daily trading volume, of 5,603,339 shares, the days-to-cover ratio is presently 2.3 days. Based on an average daily trading volume, of 5,603,339 shares, the days-to-cover ratio is presently 2.3 days. Approximately 4.9% of the shares of the stock are sold short.

Analyst Upgrades and Downgrades

AMRX has been the topic of a number of research analyst reports. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Amneal Pharmaceuticals in a research note on Wednesday, January 21st. Barclays assumed coverage on shares of Amneal Pharmaceuticals in a research note on Monday, December 8th. They set an “overweight” rating and a $15.00 target price on the stock. Truist Financial set a $15.00 target price on shares of Amneal Pharmaceuticals in a report on Wednesday, January 7th. Finally, Piper Sandler reissued an “overweight” rating and issued a $13.00 price target (up from $11.00) on shares of Amneal Pharmaceuticals in a research note on Friday, October 31st. Four analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $13.80.

Amneal Pharmaceuticals Trading Up 1.3%

Shares of AMRX opened at $14.82 on Friday. Amneal Pharmaceuticals has a 12-month low of $6.68 and a 12-month high of $15.00. The firm has a market capitalization of $4.66 billion, a P/E ratio of 741.37 and a beta of 1.36. The firm has a 50-day moving average price of $13.28 and a 200 day moving average price of $11.28.

Insider Transactions at Amneal Pharmaceuticals

In related news, Director Ted C. Nark sold 50,000 shares of Amneal Pharmaceuticals stock in a transaction dated Monday, November 17th. The stock was sold at an average price of $11.72, for a total value of $586,000.00. Following the sale, the director directly owned 291,029 shares in the company, valued at approximately $3,410,859.88. The trade was a 14.66% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Insiders own 26.56% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in AMRX. BlackBarn Capital Partners LP boosted its stake in Amneal Pharmaceuticals by 19.6% during the second quarter. BlackBarn Capital Partners LP now owns 3,446,570 shares of the company’s stock worth $27,883,000 after buying an additional 564,916 shares during the period. JPMorgan Chase & Co. raised its stake in shares of Amneal Pharmaceuticals by 22.0% in the 2nd quarter. JPMorgan Chase & Co. now owns 1,332,366 shares of the company’s stock valued at $10,779,000 after acquiring an additional 240,676 shares during the period. Allspring Global Investments Holdings LLC lifted its holdings in shares of Amneal Pharmaceuticals by 1,440.0% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 1,135,799 shares of the company’s stock worth $11,790,000 after acquiring an additional 1,062,045 shares during the last quarter. Walleye Capital LLC lifted its holdings in shares of Amneal Pharmaceuticals by 26.9% in the 2nd quarter. Walleye Capital LLC now owns 708,946 shares of the company’s stock worth $5,735,000 after acquiring an additional 150,104 shares during the last quarter. Finally, Squarepoint Ops LLC boosted its position in shares of Amneal Pharmaceuticals by 276.3% during the 2nd quarter. Squarepoint Ops LLC now owns 572,548 shares of the company’s stock worth $4,632,000 after purchasing an additional 420,398 shares during the period. 31.82% of the stock is currently owned by hedge funds and other institutional investors.

About Amneal Pharmaceuticals

Amneal Pharmaceuticals, Inc is a publicly traded integrated healthcare company specializing in the development, manufacturing and distribution of generic and specialty pharmaceutical products. The company’s portfolio includes oral solids, injectables, transdermals and biosimilars, serving a broad range of therapeutic areas such as cardiovascular, neuroscience, oncology and women’s health. Alongside its generic offerings, Amneal has built a branded portfolio through strategic acquisitions and internal development, positioning itself across both high-volume generics and higher-value specialty treatments.

Since its founding in 2002 by brothers Chirag and Chintu Modgil, Amneal has pursued growth through organic investment in research and development as well as targeted M&A.